Oragenics (OGEN) CEO/CFO receives 250,000 stock options at $0.93

Rhea-AI Filing Summary

Oragenics, Inc. reported an equity award to its CEO and CFO, Janet Huffman. On 12/11/2025 she was granted an employee stock option to buy 250,000 shares of Oragenics common stock at an exercise price of $0.93 per share under the Company's 2021 Equity Incentive Plan, as amended.

One third of the options vest on the first anniversary of the grant date, with the remaining two thirds vesting in equal annual installments on the second and third anniversaries, provided she continues to perform services for the company through each vesting date. The options are scheduled to expire on 12/11/2035, and the exercise price was set at the closing price of the common stock on the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huffman Janet

(Last) (First) (Middle)

1990 MAIN STREET, SUITE 750

(Street)

SARASOTA FL 34236

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ OGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)(1)	$0.93	12/11/2025		A		250,000(1)		(1)	12/11/2035	Common Stock	250,000	$0	250,000(1)	D

Explanation of Responses:

1. Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One third of the options vest on the first anniversary of the grant date and the remainder of the options subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant.

	/s/ Julio C. Esquivel as Attorney-In-Fact for Janet Huffman	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oragenics (OGEN) report in this Form 4?

The report shows that CEO and CFO Janet Huffman received an employee stock option covering 250,000 shares of Oragenics common stock on 12/11/2025.

What is the exercise price and term of Janet Huffmans Oragenics (OGEN) stock options?

The options have an exercise price of $0.93 per share and are scheduled to expire on 12/11/2035.

How do the new Oragenics (OGEN) options granted to the CEO/CFO vest?

One third of the 250,000 options vest on the first anniversary of the grant date, with the remaining options vesting in equal annual installments on the second and third anniversaries, subject to continued service.

Under which plan were the Oragenics (OGEN) options to Janet Huffman granted?

The award was made under Oragenics' 2021 Equity Incentive Plan, as amended.

What type of security is reported for Oragenics (OGEN) in Table II of the Form 4?

Table II reports an employee stock option (right to buy) for 250,000 shares of Oragenics common stock, held with direct ownership.